Search
PTC Therapeutics Inc
PTCTAdd to Watchlist
65.370USD
-2.630-3.87%
Close 09-18 16:00（ET）
5.45BMarket Cap
LossP/E TTM
More Details of PTC Therapeutics Inc Company
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
PTC Therapeutics Inc Profile
Ticker SymbolPTCT
Company namePTC Therapeutics Inc
IPO dateJun 20, 2013
CEOKlein (Matthew B)
Number of employees939
Security typeOrdinary Share
Fiscal year-endJun 20
Address500 Warren Corporate Center Drive
CityWARREN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07059
Phone19082227000
Websitehttps://www.ptcbio.com/
Ticker SymbolPTCT
IPO dateJun 20, 2013
CEOKlein (Matthew B)
Company Executives of PTC Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
158.60K
+0.00%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
158.60K
+0.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.39K
-7.49%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.39K
-7.49%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.57K
--
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.57K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
61.56K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
61.56K
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
24.45K
-14.29%
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
24.45K
-14.29%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
158.60K
+0.00%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
158.60K
+0.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.39K
-7.49%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.39K
-7.49%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.57K
--
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.57K
--
FAQs
Who are the top five shareholders of PTC Therapeutics Inc?
The top five shareholders of PTC Therapeutics Inc are: Mr. Michael Schmertzler
How many institutions hold shares of PTC Therapeutics Inc (PTCT)?
As of 2026Q1, 689 institutions hold shares of PTC Therapeutics Inc, with a combined market value of approximately 104.38M, accounting for 125.84% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 9374704.00.
What is the biggest source of revenue for PTC Therapeutics Inc?
In 2026Q1, the Sephience business generated the highest revenue for PTC Therapeutics Inc, amounting to 151.31M and accounting for 63.36% of total revenue.